Pre-Market Earnings Report for February 17, 2026 : MDT, ET, VMC, DTE, LH, LDOS, GPC, SGI, GMAB, CNH, ALLE, WSO

Multiple large-cap companies are scheduled to report pre-market on 02/17/2026 with published consensus EPS and analyst context: Medtronic (MDT) $1.33 (-4.32% YoY, 11 analysts), Energy Transfer (ET) $0.34 (+17.24%, 6 analysts), Labcorp (LH) $3.95 (+14.49%, 9 analysts), Leidos (LDOS) $2.57 (+8.44%, 8 analysts), Vulcan Materials (VMC) $2.13 (-1.84%, 9 analysts), Genmab (GMAB) $0.46 (-19.30%, 7 analysts) and CNH Industrial (CNH) $0.11 (-26.67%, 9 analysts) among others. Zacks-provided P/E comparisons highlight divergent valuations (e.g., MDT 17.89 vs. industry 22.90; VMC 38.23 vs. 22.90; ET 13.83 vs. industry 5.20), and the release notes recent beat/miss patterns that investors should weigh when positioning ahead of the prints. These figures suggest the prints will refine near-term stock-level positioning rather than drive broad market moves.

Analysis

Market structure: Earnings previews show bifurcation — defensive healthcare/services (LH, LDOS, DTE, MDT) to benefit from steady cashflows while cyclical industrials and discretionary names (CNH, VMC, WSO) face demand risk. Midstream Energy Transfer (ET) is supported by higher commodity-linked cashflows and should show resilience if Brent stays >$70; construction materials (VMC) are sensitive to public capex and housing activity and trade like a levered play on short-cycle demand. Competitive dynamics: firms with backlog/contracting (LDOS, DTE) can maintain pricing power; distributors like GPC will be margin- and inventory-sensitive if consumer slowdown deepens, which compresses working capital but benefits cash-rich incumbents.

Risk assessment: Tail risks include a biotech/regulatory shock at GMAB (trial failure or FDA delay) and a macro manufacturing shock that slashes CNH demand by >20% over 2 quarters. Short-term (days) volatility will be earnings-driven around Feb 17; medium-term (1–6 months) depends on CPI/Fed path and commodity prices; long-term (12+ months) depends on capex cycles and secular healthcare trends. Hidden dependencies: transportation/logistics bottlenecks and inventory gluts amplify downside for VMC/CNH beyond simple demand metrics; counterparty/distribution credit stress could rapidly hurt GPC.

Trade implications: Favor idiosyncratic longs in LH and LDOS (1–3% positions) into earnings because both have consistent beats and P/E ~14–17; avoid naked directional ahead of prints — prefer call spreads or post-earnings entries. Take tactical shorts or put spreads on CNH and WSO given consensus EPS declines (-26.7% and -18% respectively) and rich cyclicals (VMC P/E 38) with stop losses at 8–10% adverse moves. Use options: buy 30–90 day put spreads on CNH/VMC to cap risk and buy strangles on GMAB sized to 0.5–1% premium risk to capture surprise volatility.

Contrarian angles: The market underprices steady service/diagnostics winners — Labcorp (LH) may re-rate if it posts another beat and raises guide; a +5–10% move is plausible within 2–4 weeks post-earnings. Conversely, ET may be over-loved if oil drops < $65 (trigger sell), so maintain tight conditional exits. Historical parallels: post-earnings rotations in 2020–22 showed durable-service multiple expansion while cyclicals lagged for 6–12 months; similar dispersion could create pair-trade opportunities (long LH/short CNH) with asymmetric risk-reward.

Key Decisions for Investors

• Establish a 2–3% long position in Labcorp (LH) ahead of Feb 17 earnings using a 3-month 10/15% OTM call spread to limit premium and target 6–12% upside; cut to flat on a miss or if revised guide falls >5%.
• Buy a 1.5–2% notional 3-month put spread on CNH (e.g., 0% to 10% OTM) as directional hedge against the -26.7% EPS consensus drop; set profit target at 50% of max payoff and stop-loss at 60% of premium paid.
• Initiate a 1–2% long position in Leidos (LDOS) using shares or a 6-month covered-call (sell 10% OTM calls) to harvest premium while targeting 8–15% total return; exit if backlog disclosures shrink by >10%.
• Short VMC via a 3-month put spread sized to 1–1.5% notional (protective, capped risk) reflecting rich P/E (38) and cyclical downside; unwind if construction PMI holds above 50 for two consecutive months or stock falls >12%.
• Take a conservative 1–2% income-oriented position in Energy Transfer (ET) via shares for yield but overlay a 6–9 month conditional collar: sell 15% OTM calls and buy 10% OTM puts; if Brent < $65 for 2 weeks, reduce exposure by 50%.